STELARA (Ustekinumab)

STELARA (Ustekinumab)

STELARA (Ustekinumab) is an FDA-approved monoclonal antibody therapy used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease in adult patients. Each single-dose, preservative-free 1×26 mL vial contains 130 mg of Ustekinumab at 5 mg/mL, formulated for subcutaneous or intravenous administration under professional supervision.

Ustekinumab works by inhibiting interleukins IL-12 and IL-23, which play a key role in inflammatory pathways. By targeting these cytokines, STELARA helps control immune-mediated inflammation, reduce plaque formation, alleviate joint symptoms, and improve overall patient outcomes.

InfusionMed USA, based in Carrollton, Texas, supplies STELARA and other specialty dermatology and immunology infusion therapies to hospitals, clinics, and infusion centers throughout Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain compliance, proper handling, and timely delivery for healthcare providers.

For professional use only.

Download Form